Estimation of Interleukin1 Alpha and beta in serum and tissue with breast tumors patients

Main Article Content

Wurud Ali hathal, Frial Gemeel Abd

Abstract

In everyday practice, breast soft tissue lesions frequently provide a diagnostic problem. They are roughly separated into malignant and benign tumor lesions, which cover a wide range of histopathological abnormalities. This study's objective is to measure the levels of IL1 and IL1 in patients with breast cancers' serum and tissue. an example of In the period from November 2021 to November 2022, breast tissue was taken from 70 female patients (aged 14 to 66) having breast surgery in Babylon Province at AL-Hilla Teaching Hospital and AL-Fayhaa National Hospital. The women underwent lumpectomies or mastectomies for benign or harmful tumors; some had a history of breast cancer, while others did not. The tissue that was gathered for analysis was combined 5 cm outside the tumor's margin in the case of females who had tumors. Fresh tissue was immediately put in a sterilized plane tube or pee cup after circumcision. It was cut, homogenized, and had a standard saline solution. and mixed with wooden sticks using a sterile surgical knife. 30 minutes after collection Using an enzyme-linked immunosorbent assay, IL1 and IL1 were evaluated in the serum and tissue of both healthy and breast tumor-bearing women (ELISA)  The results showed that the mean of IL1 in serum of breast cancer was 1.052 and the mean of IL1 in Benign breast tumor was 1.208 that increased significantly in patients compared with control. Additionally, the mean of IL1 in serum of breast cancer was 5.287 and the mean of Benign breast tumor was 4.993 that did not increase significantly compared with control, and the mean of IL1 beta in locally was 21.000 increase significant than the mean of IL1.                                                          

Article Details

Section
Articles